en · de · es
sr9009-notes.peptides1004.com › Wiki › Background And Mechanism — 2026 Update

Background And Mechanism — 2026 Update

By Editorial Desk · published 2025-12-08 · last reviewed 2026-01-19 · Wiki

If you have been reading about Stenabolic and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Updated 2026-01-19. Numbers and descriptions here follow the published literature rather than marketing material.

Background and Mechanism

At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.

Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.

Analytical Detection and Laboratory Handling

In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.

Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.

Sr9009 at a glance

PropertyValueNotes
Molecular formulaC20H24ClN3O4SDerived from published structure.
Molecular weight437.94 g/molCalculated value.
AppearanceWhite to off-white solidTypical for purified research samples.
SolubilityDMSO, ethanol; low in waterClass: poorly water-soluble.
Typical storage-20 °C, desiccated, protected from lightLimits degradation.

SR9009 Identity and Mechanism

SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.

REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.

SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.

Related pages on this site

Supporting material

In addition, several Otago mayors including Mayor of Dunedin Sophie Barker, Mayor of Queenstown-Lakes John Glover, Mayor of Clutha Jock Martin, Mayor of Waitaki Mel Tavendale and Mayor of Central Otago Tamah Alley issued a joint statement that their councils were discussing merger options. Environment Southland chair Jeremy McPhail expressed disappointment that regional councils had been excluded from making proposals on the amalgamation process but said they would continue advocating.

=== 1973 to 2009 === Hanmi was founded in 1973 by Lim Sung-ki, who was a pharmacist. It was originally named Lim, Sung-ki Pharmaceutical Co., but it was quickly changed to Hanmi Pharmaceutical. The company originally started selling Trimethoprim/sulfamethoxazole powder, and would expand to produce Cephalosporin antibiotics in 1985 and injectable Ceftriaxone antibiotics in 1987. By 1988 the company was listed in the Korea Exchange. Hanmi started selling drugs in China in 1996. In 1994, the company began developing Cyclosporin. The company broke the ₩100,000,000,000 barrier in sales in 1997. The company began moving into the European market in 1998. The company still was developing new drugs, with Paclitaxel in 2000, Itraconazole tablets in 2001, 24-hour controlled-release Nifedipine tablets and a new salt form of Amlodipine in 2004, and an anti-obesity drug using sibutramine mesilate in 2007. Hanmi and Crystal Genomics formed a strategic partnership in 2008.

The district's borders, which correspond to the former city's borders, are: Victoria Park Avenue (facing the rest of Toronto) to the west, the Rouge River, the Little Rouge Creek and the Scarborough-Pickering Townline (facing Pickering) to the east, Steeles Avenue (facing Markham) to the north, and Lake Ontario to the south. Topographically, the district is dominated by two watersheds, Highland Creek and the Rouge River. Highland Creek lies almost entirely within Scarborough and occupies approximately 70% of its total area. It occupies the western half of Scarborough, while the Rouge River flows through the eastern portion. Both of these rivers flow into Lake Ontario. Due to the location of the Lakeshore CN railway right-of-way, both river deltas are constricted to narrow channels where they flow into the lake. Highland Creek is the most urbanized watershed in Toronto with about 85% of its land use devoted to urban uses. Some sections of the river run through parks and remain in a fairly natural state, while other parts run through industrial or residential districts where the flow is often diverted or channelled. Sections of the creek are marked by deep ravines and valleys, which contain little or no urban development. The deep valley the creek cuts in its bottom sections remains primarily parkland, with little or no development taking place within the valley. Conversely, the Rouge River valley has parts which are still in a natural, wooded state.

Sources: en.wikipedia.org

Supporting material

PAHs may be abundant in the universe. They seem to have been formed as early as a couple of billion years after the Big Bang, and are associated with new stars and exoplanets. More than 20% of the carbon in the universe may be associated with PAHs. PAHs are considered possible starting material for the earliest forms of life. Light emitted by the Red Rectangle Nebula possesses spectral signatures that suggest the presence of anthracene and pyrene. This report was considered a controversial hypothesis that as nebulae of the same type as the Red Rectangle approach the ends of their lives, convection currents cause carbon and hydrogen in the nebulae's cores to get caught in stellar winds, and radiate outward. As they cool, the atoms supposedly bond to each other in various ways and eventually form particles of a million or more atoms. Adolf Witt and his team inferred that PAHs—which may have been vital in the formation of early life on Earth—can only originate in nebulae.

On 23 August, groups of the National Guard affiliated with Suleiman al-Hijri, son of Hikmat al-Hijri, closed and blocked the Umm al-Zaytoun checkpoint, preventing students from taking their exams. On 27 August, the Shahba Operations Room, affiliated with the National Guard, warned drivers and means of transport that they would not transport students and that if they violated the warning, they would be penalized. On 28 August, in the villages of Sala and Rashida, a 30-year-old man died after a clash with the National Guard, after the National Guard tried to arrest him. That same day, clashes broke out between the National Guard after militias laid siege to Rami Ishti and Ghaith Qantar in Ariqa, then militias affiliated with Nawras Azzam, a leader of the National Guard's security office, broke the siege.

=== Sample collection === Newborn screening tests are most commonly done from whole blood samples collected on specially designed filter paper, originally designed by Robert Guthrie. The filter paper is often attached to a form containing required information about the infant and parents. This includes date and time of birth, date and time of sample collection, the infant's weight and gestational age. The form will also have information about whether the baby has had a blood transfusion and any additional nutrition the baby may have received (total parenteral nutrition). Most newborn screening cards also include contact information for the infant's physician in cases where follow up screening or treatment is needed. The Canadian province of Quebec performs newborn screening on whole blood samples collected as in most other jurisdictions, and also runs a voluntary urine screening program where parents collect a sample at 21 days of age and submit it to a provincial laboratory for an additional panel of conditions. Newborn screening samples are collected from the infant between 24 hours and 7 days after birth, and it is recommended that the infant has fed at least once. Individual jurisdictions will often have more specific requirements, with some states accepting samples collected at 12 hours, and others recommending to wait until 48 hours of life or later. Each laboratory will have its own criteria on when a sample is acceptable, or if another would need to be collected. Samples can be collected at the hospital, or by midwives.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.

Is SR9009 a SARM?

No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.

Are there human trials of SR9009?

Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.

How is SR9009 detected?

It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.

Network